

## Response to Comment on: a case series of patients with $\beta$ -thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies

by Fabiana Busti and Domenico Girelli

Received: August 28, 2025.

Accepted: September 2, 2025.

Citation: Fabiana Busti and Domenico Girelli. Response to Comment on: A case series of patients with  $\beta$ -thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies.

Haematologica. 2025 Sept 11. doi: 10.3324/haematol.2025.289073 [Epub ahead of print]

### *Publisher's Disclaimer.*

E-publishing ahead of print is increasingly important for the rapid dissemination of science.

Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.

E-publishing of this PDF file has been approved by the authors.

After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.

All legal disclaimers that apply to the journal also pertain to this production process.

**Response to Comment on: a case series of patients with  $\beta$ -thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies**

Fabiana Busti<sup>\*1,2</sup> and Domenico Girelli<sup>1,2</sup>

<sup>1</sup> Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

<sup>2</sup> Veneto Region Referral Center for Iron Disorders and European Reference Network Center for Rare Hematological Diseases "EuroBloodNet"

\* Corresponding author ([fabiana.busti@univr.it](mailto:fabiana.busti@univr.it))

**Author's contribution:** F.B. and D.G. co-wrote the response.

**Disclosures:** D.G. is a consultant for Sanofi, Kedrion-Pharmacosmos, Vifor Pharma, and Novo Nordisk. F.B. has no conflict of interest to disclose.

We sincerely thank Prof. Piperno and colleagues for their comment (1) on our work (2). We fully agree on the importance of not overlooking hyperferritinemia in beta-thalassemia trait (BTT) patients, a condition often underestimated. In the suspicion of iron overload, liver magnetic resonance imaging (MRI) should be offered for accurate assessment of parenchymal iron burden, and standardized diagnostic cut-offs are needed to better stratify risk and guide treatment decisions.

Our study showed that mini-phlebotomies are an effective and well-tolerated approach, although sometimes prolonged treatment may be required. Subcutaneous bolus of desferrioxamine, while theoretically feasible, remains scarcely explored in the literature and seldom used in clinical practice (3). Therefore, we agree that, in selected cases, such as patients with moderate anemia or severe iron overload, access to other effective therapies should be considered. Oral iron chelators, already validated in transfusion- and non-transfusion-dependent thalassemias (NTDT) (4), may represent a more practical option, but their use should be restricted to carefully selected patients, as they are not devoid of risks, particularly concerning renal, gastrointestinal, visual, and hearing toxicity.

Given the high prevalence of BTT and the fact that a subset of individuals may develop clinically relevant multifactorial iron overload, further studies are warranted to explore novel therapeutic approaches, including oral iron chelators, in this underserved population.

**References:**

1. Piperno A, Mariani R. Beta-thalassemia thalassemia trait and iron overload: is it time to consider oral iron chelators? Comments on: A case series of patients with  $\beta$ -thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies. *Haematologica*. xxx
2. Busti F, Castagna A, Marchi G, et al. A case series of patients with  $\beta$ -thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies. *Haematologica*. 2025;110(5):1226-1231.
3. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. *Blood*. 2000;95(9):2776-2779.
4. Cappellini MD, Scaramellini N, Leoni S, Motta I. Iron Chelation Therapy. *Adv Exp Med Biol*. 2025;1480:361-370.